PBMs also set the utilization controls that help balance access and affordability, such as prior authorization, step therapy, and BMI or diagnosis requirements for weight-management use
Wharton S, Calanna S, Davies M, Dicker D, Goldman B, Lingvay I, Mosenzon O, Rubino DM, Thomsen M, Wadden TA, Pedersen SD
But the details in individual reviews reveal the patterns that matter most
By now you know that the FDA has approved three medications with semaglutide: Ozempic, Rybelsus, and Wegovy, all of which are GLP-1 receptor agonists
Substrate profiling of glutathione S-transferase with engineered enzymes and matched glutathione analogues
Eli Lilly and Co, on the other hand, produces Zepbound and Mounjaro, tirzepatide brand-name medications